Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T18972
|
||||
Former ID |
TTDNC00504
|
||||
Target Name |
CD3
|
||||
Gene Name |
CD3G
|
||||
Synonyms |
CD3g; T-cell receptor T3 gamma chain; T-cell surface glycoprotein CD3 gamma chain; CD3G
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Advanced breast cancer [ICD9: 174, 175; ICD10: C50] | ||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Colorectal cancer [ICD9: 153, 154; ICD10: C18-C21] | |||||
Gastrointestinal adenocarcinoma [ICD10: C15-C26] | |||||
Non-hodgkin's lymphoma [ICD10: C85] | |||||
Prostate cancer [ICD9: 185; ICD10: C61] | |||||
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48] | |||||
Function |
The CD3 complex mediates signal transduction.
|
||||
UniProt ID | |||||
Sequence |
MEQGKGLAVLILAIILLQGTLAQSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGK
MIGFLTEDKKKWNLGSNAKDPRGMYQCKGSQNKSKPLQVYYRMCQNCIELNAATISGFLF AEIVSIFVLAVGVYFIAGQDGVRQSRASDKQTLLPNDQLYQPLKDREDDQYSHLQGNQLR RN |
||||
Drugs and Mode of Action | |||||
Drug(s) | Ertumaxomab | Drug Info | Phase 2 | Breast cancer | [529707], [531972] |
AFM11 | Drug Info | Phase 1 | Non-hodgkin's lymphoma | [524703] | |
Autologous T-cell therapy | Drug Info | Phase 1 | Prostate cancer | [525412] | |
Ertumaxomab | Drug Info | Phase 1 | Advanced breast cancer | [889343] | |
MEDI-565 | Drug Info | Phase 1 | Gastrointestinal adenocarcinoma | [523334] | |
MGD007 | Drug Info | Phase 1 | Colorectal cancer | [889404] | |
MT-110 | Drug Info | Phase 1 | Solid tumours | [531707] | |
Pathways | |||||
KEGG Pathway | Hematopoietic cell lineage | ||||
T cell receptor signaling pathway | |||||
Chagas disease (American trypanosomiasis) | |||||
Measles | |||||
HTLV-I infection | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | T cell activation | ||||
Pathway Interaction Database | TCR signaling in na& | ||||
#xef | |||||
ve CD4+ T cells | |||||
IL12-mediated signaling events | |||||
TCR signaling in na& | |||||
ve CD8+ T cells | |||||
CXCR4-mediated signaling events | |||||
Downstream signaling in na& | |||||
IL12 signaling mediated by STAT4 | |||||
Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | ||||
Phosphorylation of CD3 and TCR zeta chains | |||||
Translocation of ZAP-70 to Immunological synapse | |||||
Generation of second messenger molecules | |||||
FCGR activation | |||||
Regulation of actin dynamics for phagocytic cup formation | |||||
Role of phospholipids in phagocytosis | |||||
PD-1 signaling | |||||
WikiPathways | TCR Signaling Pathway | ||||
Fcgamma receptor (FCGR) dependent phagocytosis | |||||
TCR signaling | |||||
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||||
Costimulation by the CD28 family | |||||
References | |||||
Ref 523334 | ClinicalTrials.gov (NCT01284231) A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas. U.S. National Institutes of Health. | ||||
Ref 524703 | ClinicalTrials.gov (NCT02106091) Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL or B-precursor ALL. U.S. National Institutes of Health. | ||||
Ref 525412 | Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology. 2014 May 16;3(5):e16. doi: 10.1038/cti.2014.7. eCollection 2014. | ||||
Ref 529707 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. | ||||
Ref 531707 | EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. | ||||
Ref 531972 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. | ||||
Ref 529707 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. | ||||
Ref 531707 | EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74. | ||||
Ref 531972 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.